This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Calmark Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Calmark Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Calmark Sweden Relaunches Point-of-Care Instrument in Finland MT
Calmark Sweden AB Relaunches Neo-Bilirubin in Finland CI
Calmark Sweden Wins Repeat Order for Point-of-Care Instrument in Greece MT
Calmark Sweden Secures Test Casette Patent in India MT
Calmark Sweden Secures Vietnam Patent for POC Test System for Biomarker MT
Calmark Sweden AB Signs Distributorship Agreement with Techno Orbits in Saudi Arabia CI
Calmark Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Calmark Sweden Nears US Patent Approval for Test Cassette Design MT
Calmark Sweden AB Ships Instruments to India for A Method Comparing Study CI
Calmark Sweden to Deliver Test Cassettes to Global Health Labs MT
Calmark Sweden Plans Capital Raise to Fund Operations MT
Calmark Sweden Wins Order for Neo Platform in Turkey MT
Calmark Sweden AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Calmark Receives First Demo Order in Puerto Rico MT
Calmark Receives Additional Order from Italy for Test Cassettes MT
Calmark Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Calmark Sweden Secures First Order From Swedish Distributor MT
Calmark Sweden AB Receives Order from Mediq in Sweden CI
Calmark Sweden Signs Bilirubin Test Distributor Agreement in Turkey MT
Calmark Sweden AB Signs Distributor Agreement with Savas Medikal in Turkey CI
Calmark Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Calmark Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Calmark Sweden to Dissolve Chinese Subsidiary Wuxi, Retain Hong Kong Unit MT
Chart Calmark Sweden AB
More charts
Calmark Sweden AB is a Sweden-based Company providing patient-near-term testing (PNA) specialized in newborns. Its main focus is to develop medical diagnostic biotechnology. The Company focuses on the development of solutions for point-of-care detection of critical illness. Calmark Sweden AB supports physicians and other healthcare professionals to detect illness independently of the cause and regardless of the symptoms.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. CALMA B Stock
  4. News Calmark Sweden AB
  5. Calmark Sweden Secures Vietnam Patent for POC Test System for Biomarker